Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer
The goal of this clinical trial is to evaluate safety of delivering Aliya PEF in patients with metastatic cancer within the lungs or stage IV non-small cell lung cancer (NSCLC) who are treatment-naïve and indicated for first-line standard of care (SOC) cancer therapy.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Aug 20, 2025 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Galvanize Therapeutics, Inc.
- Interventions being studied
- Device: Aliya Pulsed Electric Fields (PEF)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Patient has suspected or confirmed metastatic cancer within the lungs, or stage IV non-small cell lung cancer (NSCLC) requiring biopsy.
- Patient has radiologically documented suspected, or confirmed tumor(s) that are ≤ 5 cm in longest diameter and deemed by the investigator to be suitable per study procedural guidelines for treatment with PEF.
- Patient is deemed eligible to receive 1L SOC therapy for their malignancy.
- In the opinion of the investigator, the patient is not a surgical candidate for curative intent, or the patient has refused surgery.
- Life expectancy ≥ 6 months.
- Patient has received any prior cancer therapy for current tumor(s) to be treated with PEF.
- Patient is scheduled to receive investigational therapies (including device-based therapy) that may interfere with the study endpoints while on this study.
- Patient has clinical evidence of leptomeningeal disease or brain metastases that require SOC treatment within 4 weeks post-PEF treatment.
- Patient with active, known, or suspected autoimmune disease.
- Patient with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
- Patient has received systemic treatment with corticosteroids (\> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 30 days prior to study enrollment. Inhaled or topical steroids, and adrenal replacement doses \> 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease.
- Patient has any history of primary immunodeficiency.
- Patient has clinical signs or symptoms of active tuberculosis infection.
- Patient has documented evidence of acute hepatitis or has an active or uncontrolled infection.
- Patient has undergone major surgery (excluding placement of vascular access) within 28 days prior to study enrollment or has planned major surgeries while enrolled in the study, Other protocol defined inclusion/
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Mayo ClinicJacksonville, Florida
- Mayo Clinic RochesterRochester, Minnesota
- Weill Cornell Medicine | New York-PresbyterianNew York, New York
- FirstHealth of the Carolinas, Inc.Pinehurst, North Carolina
- University of PennsylvaniaPhiladelphia, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 20, 2025. Always confirm current availability with the study team.